#United States #Parkinson's Disease #Brenig Therapeutics #BT-267 #Dover

Brenig Therapeutics Begins Groundbreaking Clinical Trial for BT-267

Brenig Therapeutics, a pioneering biotechnology firm focused on advancing treatments for neurodegenerative diseases, recently announced the commencement of its first-in-human clinical trial for a novel therapy called BT-267. This innovative drug is classified as a best-in-class LRRK2 inhibitor and is being investigated as a potential disease-modifying treatment for both idiopathic and LRRK2-associated Parkinson's disease.

The clinical trial began in November 2024 and marks a significant milestone in Brenig's clinical program, which was bolstered by a substantial $65 million financing round led by New Enterprise Associates. This financial support demonstrates confidence in BT-267's potential and reflects the growing interest in innovative therapies for Parkinson's disease.

The initial phase of this trial focuses on assessing the safety and tolerability of BT-267 in healthy volunteers. Following this preliminary evaluation, Brenig plans to move forward with proof-of-concept studies involving patients suffering from idiopathic Parkinson's disease. This strategic approach will ensure a thorough understanding of the drug's effects before larger, more comprehensive trials with affected populations are conducted.

Preclinical studies present compelling data suggesting that BT-267 could be a standout LRRK2 inhibitor on the market. Findings indicate a superior safety profile with minimal indications of lung or kidney damage at the highest tested doses during GLP toxicology studies. Furthermore, the pharmacokinetic profile of BT-267 appears promising, showing a high ratio of cerebrospinal fluid (CSF) to plasma unbound concentration—a crucial factor for therapies targeting neurodegenerative diseases.

Brenig's innovative approach utilizes advanced methodologies, including computer-aided drug design, AI and machine learning in computational pharmacology, and biomarker modeling. These cutting-edge technologies, combined with the structural biology expertise from the collaboration with Expert Systems Accelerator, enhance Brenig's efforts in identifying predictive biomarkers and positioning BT-267 as a promising candidate for disease-modifying therapy—particularly for idiopathic Parkinson's cases that lack clear genetic indicators.

As Parkinson's disease continues to affect millions globally, the initiation of this clinical trial represents a beacon of hope. Brenig Therapeutics is driven by a commitment to addressing fundamental causes of neurodegenerative conditions through groundbreaking science and patient-centered approaches. With BT-267, the company aims not only to develop effective treatments but also to improve the quality of life for those battling Parkinson's disease.

About Brenig Therapeutics

Brenig Therapeutics stands at the forefront of biotechnology, dedicated to revolutionizing treatments for neurodegenerative diseases. The company leverages state-of-the-art research methodologies and an unwavering focus on the needs of patients, with the goal of delivering transformative solutions that combat these debilitating illnesses.

For more information or media inquiries, reach out to:
Dana Hilt, MD PhD
Chief Medical Officer
Brenig Therapeutics
[email protected]